Brazilian Regulator Approves Sinovac’s Phase 3 COVID-19 Vaccine Trial

Beijing-based Sinovac has received approval from Brazil’s Health Regulatory Agency to begin phase 3 trials of CoronaVac, its COVID-19 vaccine candidate, and said it plans to begin enrollment this month.

The experimental vaccine uses an inactivated form of the coronavirus to generate an immune response. The phase 3 study will include 9,000 healthcare professionals across 12 clinical sites.

CoronaVac showed promise in a phase 2 clinical trial, in which it induced neutralizing antibodies in 90 percent of participants.